1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Brain cancers

Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)

Technology appraisal guidance [TA23] Published date: 26 April 2001 Last updated: 03 March 2016

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Documents

A list of downloadable documents created during development.

Review proposal consultation

  • Review proposal consultation  
  • Stakeholder matrix PDF 104.42 KB 07 January 2016  
  • Review proposal paper PDF 240.5 KB 07 January 2016  

Other information

  • TA23 Brain cancer - temozolomide: summary PDF 42.02 KB 04 November 2002  

Background information

  • TA23 Brain cancer - temozolomide: review decision - May 2011 information  
  • Appendix A: decision paper presented to the Institute's Guidance Executive PDF 63.07 KB 11 May 2011  
  • Review decision information  
  • TA23 Brain cancer - temozolomide: HTA report information  
  • TA23 Brain cancer - temozolomide: HTA report PDF 311.54 KB 27 April 2001  
  • TA23 Brain cancer - temozolomide: review proposal - March 2011 information  
  • Appendix A: provisional matrix of stakeholders PDF 18.01 KB 25 March 2011  
  • Appendix B: proposal paper presented to the Institute's Guidance Executive PDF 230.93 KB 25 March 2011